LGND News and Press, Ligand Pharmaceuticals Incorporated From 05/26/21

The FDA has accepted with priority review the BLA for Johnson & Johnson (JNJ) Janssen unit's ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma.The PDUFA date is November 29, 2021.Janssen began a rolling submission of the CAR-T therapy in December.J&a...

I looked inside our U.S. small-cap Funds to see which of the major meme stocks are in our ETFs. I think I captured most of the main ones from the frenzy. Another Index that we think could be ripe for a “GameStopping” is the Russell Microcap Index, which tracks the 1,000 ...

Ligand Pharmaceuticals (NASDAQ: LGND) stock skyrocketed earlier this year. However, the short squeeze that fueled those massive gains is now over . That means that Ligand probably needs a more conventional catalyst to go on another run. The company announced its first-quarte...

Image source: The Motley Fool. Ligand Pharmaceuticals Inc (NASDAQ: LGND) Q1 2021 Earnings Call May 3, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Ligand Pharmaceuticals Inc (LGND) Q1 2021 Earnings Call Transcrip...

Ligand Pharmaceuticals Incorporated (LGND) Q1 2021 Earnings Conference Call May 03, 2021, 2:30 PM ET Company Participants John Higgins - Chief Executive Officer Matthew Korenberg - Executive Vice President, Finance and Chief Financial Officer Matthew Foehr - President and Chief Operating Offi...

Ligand Phaarmaceuticals (LGND) swung to a Q1 profit, helped by a ~48% year-over-year increase in sales of Captisol to $31.3M.The company said the boost in Capitol sales was in large part due to its use with Gilead's COVID-19 trteatment Veklury (remdesivir).Net income in Q1 was $18.1M ($1.05 p...

Ligand Pharmaceuticals (LGND): Q1 Non-GAAP EPS of $1.41 beats by $0.28; GAAP EPS of $1.05 beats by $0.67.Revenue of $55.15M (+66.3% Y/Y) misses by $7.85M.Ligand today affirms its guidance for 2021 total revenues to be approximately $291 million and 2021 adjusted earnings per diluted share to ...

Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2021 and provided an operating forecast and program updates. Ligand management will host a conf...

[[ADUS]], [[AGR]], [[AWK]], [[AWR]], [[BLDP]], [[BRX]], [[BWXT]], [[CAR]], [[CBT]], [[CC]], [[CHGG]], [[CR]], [[EVER]], [[FANG]], [[FLS]], [[FN]], [[FRPT]], [[HLIT]], [[IAG]], [[IRBT]], [[JKHY]], [[KFRC]], [[KMT]], [[LEG]], [[LGND]], [[LTHM]], [[MAXR]], [[MOS]], [[MWA]], [[MYGN]], [[NSP]], [[...

Ligand Pharmaceuticals (NASDAQ:LGND) is scheduled to announce Q1 earnings results on Monday, May 3rd, after market close.The consensus EPS Estimate is $1.13 (+27.0% Y/Y) and the consensus Revenue Estimate is $63M (+90.0% Y/Y).Over the last 2 years, LGND has beaten EPS estimates 100% of the ti...